Is Wall Street Bullish or Bearish?

Kenvue Inc. (Kvue, based in Kvue, is a consumer health company that operates throughout the Americas, Europe, EMEA and Indo-Pacific. It works through self -care, health, beauty, and basic health sectors. The maximum market of $ 42.9 billion, Kenvue has many known brands such as Listerine, Band-Aid, Tylenol, Neutrogena and more.

The company led to the weakness of the broader market in 2025, but it surpassed over the past year. KVUE stock increased by 3.8 % on the basis of YTD and increased by 17.9 % over the past 52 weeks, compared to an increase of the S&P 500 ($ Spx) 8.3 % in 2025 and 16.6 % during the past year.

Focus narrowing, Kenvue also outperformed the SPDR SPDR SPDR SECTOR SCTOR SPDR by 3.3 % on the basis of YTD and 3.4 % returns over the past year.

Kenvue stock prices increased by 4.1 % after the results of the first quarter of the expected quarter of May. Due to a decrease in organic sales and the opposite currency, the company’s net sales for a quarter decreased by 3.9 % on an annual basis to $ 3.7 billion. However, the number estimated the consensus by 1.7 %. Meanwhile, the profitability of the amended arrow from Kenvue decreased by 14.3 % year on an annual basis to $ 0.24, but exceeded the street expectations by 9.1 %, which strengthened the investor confidence.

Analysts expect Kenvue to report a 2.6 % decrease on an annual basis in the profitability of the modified arrow to $ 1.11 for the fiscal year 2025, and ends in December. However, the company has a sudden history of profits. It has exceeded or fulfilled street expectations in both the past four quarters.

The arrow contains a “moderate purchase” classification in general. Among the 15 analysts covering the arrow, it recommends five “strong purchases” while proposing 10 “Hold” categories.

This configuration is slightly lower than two months ago, when six analysts made “strong purchase” recommendations.

On July 25, Andrea Varia’s JPM MOPM (JPM) analyst, “Buy” on Kvue, but reduced the target price to $ 26.

The average medium price of Kenvue of $ 23.89 suggests 7.8 % of current price levels, while the high target in the street of $ 29 represents a premium of 30.8 % to the current price levels.

On the date of publication, Aditya Sarawi did not have positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are only for media purposes. This article was originally published on Barchart.com